- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05541419
Use of Budesonide Diluted to Maximum Clinical Treatment of Patients With Chronic Rhinosinusitis With Polyoposis. (CRS)
Efficacy of Addition of High-volume Nasal Wash With Budesonide Diluted to Maximum Clinical Treatment of Patients With Chronic Rhinosinusitis With Polyoposis: Double, Randomized, Controlled Double Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Marco Aurélio Fornazieri
- Phone Number: +55 43 99813-3812
- Email: marcofornazieri@gmail.com
Study Locations
-
-
Paraná
-
Londrina, Paraná, Brazil, 86010-160
- Recruiting
- Marco Aurelio Fornazieri
-
Contact:
- Marco A Fornazieri
- Phone Number: 4330291436
- Email: marcofornazieri@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A minimum nasal polyp score (NPS) of 5 of a maximum of 8 for both nostrils (with at least a score of 2 for each nostril).
- Presence of at least two of the following symptoms prior to screening: nasal blockage / obstruction / congestion or rhinorrhea (anterior or posterior); facial / pressure pain; reduction or loss of smell.
Exclusion Criteria:
- A patient under the age of 18, or over 55;
- SNOT-22 with sum of less than 7;
- Patients who have used drugs or therapies that interfere with the results of this clinical trial within 2 months prior to screening: treatment with immunosuppressants; anti-immunoglobulin and within two months prior to screening.
- Initiation of allergen immunotherapy within 3 months prior to first consultation or plan to initiate therapy during the screening period or randomized treatment period;
- Patients who underwent any nasal surgery;
- Patients on anti-leukotrienes and antihistamines
- Asthmatic patients will be excluded if: forced expiratory volume (FEV1) is 60% predicted or lower; an exacerbation requiring systemic (oral and / or parenteral) or hospitalization for more than 24 hours for the treatment of asthma has occurred within 3 months prior to screening; use of a dose greater than 1000 μg of inhaled fluticasone or equivalent;
- Patients with a short life expectancy (less than 6 months);
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Maximum clinical treatment + Budesonide diluted
The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril. In this study, the investigator wishes to add to the maximum clinical treatment a daily wash with high volume diluted budesonide. |
The patient performed a lavage once daily with 2mg dilute budesonide.
The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
Other Names:
|
Placebo Comparator: Maximum clinical treatment + Placebo
To compare the efficacy of adding diluted budesonide lavage to maximal clinical treatment, the placebo group is used.
The placebo formula is composed of 1% glycerin diluted in water.
|
Composed of 1% glycerin diluted in water.
The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the improvement in the Nasal Polyp Score
Time Frame: 16 weeks
|
To verify, from the change in the Nasal Polyp Score (NPS, range from 0 to 8, higher score indicates larger polyp size), the impact of maximum clinical treatment - intramuscular injection of Dispropan in intramuscular injectable suspension and budesonide in nasal spray, two sprays of 50 mcg in each nostril - plus high-volume diluted budesonide nasal lavage, compared to the same maximum clinical treatment plus high-flow placebo nasal lavage in patients with chronic rhinosinusitis with polyposis without previous nasal surgery for a period of 16 weeks.
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improves olfactory ability through the University of Pennsylvania Smell Identification Test
Time Frame: 16 weeks
|
UNIVERSITY OF PENNSYLVANIA SMELL IDENTIFICATION TEST (UPSIT) - This instrument consists of four cards of 10 odors, with one odor per page.
The stimuli are embedded in plastic microcapsules present in a brown band at the bottom of each page.
The examiner directs the person being examined to scrape this strip with a pencil, which causes the odor to be released.
After that, the patient answers a multiple choice question to describe what the odor looks like.
Based on the score obtained, the individual's olfactory function can be classified into normosmia, microsmia (mild, moderate and severe) and anosmia (Fornazieri et al., 2010).
This test has been validated for the Brazilian population (Fornazieri et al., 2015).
|
16 weeks
|
Sino-Nasal Outcome Test - 22 (SNOT-22)
Time Frame: 16 weeks
|
The Sino-Nasal Outcome Test - 22 consists of a questionnaire consisting of 22 questions that assess the severity of nasal symptoms reported by the patient on a scale from 0 to 5 in each question, with a score of 5 being the greatest discomfort to the patient.
The questions that make up the SNOT-22 refer to rhinological, otological, facial symptoms (12 questions) and their impact on quality of life (10 questions), which cover sleep function and psychological impairment.
The questionnaire, as a whole, includes symptoms such as the need to blow nose, sneezing, rhinorrhea, cough, posterior rhinorrhea, thick rhinorrhea, ear fullness, dizziness, otalgia, facial pain or pressure, difficulty initiating sleep, fatigue on awakening, reduced of productivity and concentration, frustration, sadness and irritability (Piccirillo, Merritt and Richards, 2002; Hopkins et al., 2009).
|
16 weeks
|
Analogic visual scale (VAS)
Time Frame: 16 weeks
|
The visual analogue scale for chronic rhinosinusitis is used to assess the severity of symptoms and their impact on the patient's quality of life, based on the question: "How problematic are your symptoms of rhinosinusitis?". The patient should mark, on a 10 centimeter line graduated on a scale from zero to ten, the severity of the symptoms reported, with zero representing no discomfort, and ten representing the greatest possible discomfort (Fokkens, Lund and Mullol, 2007) (Bachert et al., 2016). The disease can be divided into: Mild = patient scores between 0 and 3; Moderate = patient scores between 3 and 7; Severe = patient scores between 7 and 10. |
16 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Otorhinolaryngologic Diseases
- Paranasal Sinus Diseases
- Nose Diseases
- Sinusitis
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Budesonide
Other Study ID Numbers
- MFornazieri
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Rhinosinusitis (Diagnosis)
-
Christiane HaaseActive, not recruitingAsthma | Chronic Rhinosinusitis (Diagnosis) | Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsDenmark
-
Johns Hopkins UniversityGlaxoSmithKlineRecruitingChronic Rhinosinusitis (Diagnosis) | Chronic Rhinosinusitis With Nasal PolypsUnited States
-
Washington University School of MedicineCompletedChronic Rhinosinusitis (Diagnosis) | Allergic Rhinosinusitis | Chronic Eosinophilic RhinosinusitisUnited States
-
Lyra TherapeuticsRecruitingChronic Sinusitis | Chronic Rhinosinusitis (Diagnosis)United States, Poland, Bulgaria, Belgium, Germany, Hungary
-
Medical University of ViennaRecruitingAsthma | Chronic Rhinosinusitis (Diagnosis) | Nasal Polyps | Chronic Rhinosinusitis With Nasal PolypsAustria
-
Sohag UniversityNot yet recruitingRhinosinusitis Chronic | Rhinosinusitis | Fungal Sinusitis | Rhinosinusitis Acute | Allergic Fungal Rhinosinusitis | Intracranial Extension | Invasive Fungal Sinusitis (Diagnosis)Egypt
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...RecruitingAsthma | Chronic Rhinosinusitis (Diagnosis) | Chronic Rhinosinusitis With Nasal PolypsUnited States
-
Oticara Australia PTY LTDRecruitingChronic Rhinosinusitis (Diagnosis)Australia
-
Intersect ENTCompletedChronic Rhinosinusitis (Diagnosis)United States
-
Sanna SalmiUniversity of HelsinkiActive, not recruitingChronic Rhinosinusitis (Diagnosis)Finland
Clinical Trials on Budesonide Nasal
-
Istituto per la Ricerca e l'Innovazione BiomedicaCompleted
-
Yale UniversityCompleted
-
Khon Kaen UniversityUnknownChronic Frontal Rhinosinusitis | Vertex to Floor PositionThailand
-
Guangzhou Institute of Respiratory DiseaseCompletedRespiratory Tract Diseases | Inflammation | Hypersensitivity | Allergic RhinitisChina
-
Lawson Health Research InstituteWithdrawn
-
University of British ColumbiaJohnson & Johnson Consumer Inc. (J&JCI); Genome British ColumbiaActive, not recruitingEnvironmental Exposure | Epigenetic Effects of Intranasal SteroidsCanada
-
Fondation Ophtalmologique Adolphe de RothschildHopital LariboisièreCompletedAnosmia | SARS-CoV-2 | Olfaction Disorders | BudesonideFrance
-
St. Paul's Hospital, CanadaCompleted
-
Cliniques universitaires Saint-Luc- Université...CompletedProstatic NeoplasmBelgium